Compare KRMD & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | CRNX |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.7M | 3.9B |
| IPO Year | 2019 | 2018 |
| Metric | KRMD | CRNX |
|---|---|---|
| Price | $4.22 | $33.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $6.50 | ★ $74.78 |
| AVG Volume (30 Days) | 137.3K | ★ 1.0M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | $1,039,000.00 |
| Revenue This Year | $20.32 | $722.66 |
| Revenue Next Year | $17.38 | $183.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $1.87 | $24.10 |
| 52 Week High | $6.61 | $57.99 |
| Indicator | KRMD | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 29.20 |
| Support Level | $4.08 | $33.23 |
| Resistance Level | $4.34 | $37.23 |
| Average True Range (ATR) | 0.20 | 1.62 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 23.36 | 8.33 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.